SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants.

ABSTRACT: Pharmacotherapies for the treatment of major depressive disorder were serendipitously discovered almost seven decades ago. From this discovery, scientists pinpointed the monoaminergic system as the primary target associated with symptom alleviation. As a result, most antidepressants have been engineered to act on the monoaminergic system more selectively, primarily on serotonin, in an effort to increase treatment response and reduce unfavorable side effects. However, slow and inconsistent clinical responses continue to be observed with these available treatments. Recent findings point to the glutamatergic system as a target for rapid acting antidepressants. Investigating different cohorts of depressed individuals treated with serotonergic and other monoaminergic antidepressants, we found t

SUBMITTER: Lin R 

PROVIDER: S-EPMC10335830 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature